Beckman Selects Fisher Unit, Cellomics, to Provide Ongoing Service for HCS Customers
News Jun 14, 2006
This agreement covers the Beckman Coulter Cell Lab IC 100 Image Cytometer and the EIDAQ 100 High-Throughput Microscopy System.
Beckman Coulter recently announced that it would no longer market these products but would continue to support existing customers.
"Our primary goal in reaching this agreement was to provide ongoing support for our customers," said Karen Bezold, director of Research Cytometry, Beckman Coulter, Inc.
"With Cellomics’ expertise in the HCS field, we are confident our customers will have the best possible support going forward."
Beckman Coulter will continue to focus its research cytometry business on flow cytometry and particle characterization.
"Our agreement with Beckman Coulter is an affirmation of Cellomics’ technology leadership and service excellence," said Ron Lowy, president and chief executive officer of Fisher Biosciences.
"We have the expertise to answer virtually any question concerning HCS and help customers solve any technical problems they may encounter."
"We are excited about the opportunity to serve another group of customers who are interested in HCS technology."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.